Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer

Everolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is effective in treating tumors harboring alterations in the mTOR pathway. Mechanisms of resistance to everolimus remain undefined. Resistance developed in a patient with metastatic anaplastic thyroid carcinoma after an extraordin...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Van Allen, Eliezer M., Amin-Mansour, Ali, Taylor-Weiner, Amaro, Rosenberg, Mara, Barletta, Justine A., Guo, Yanan, Swanson, Scott J., Ruan, Daniel T., Hanna, Glenn J., Haddad, Robert I., Kwiatkowski, David J., Jänne, Pasi A., Lorch, Jochen H., Wagle, Nikhil, Grabiner, Brian, Gray, Nathanael S, Getz, Gad Asher, Carter, Scott, Sabatini, David, Garraway, Levi A.
Rannpháirtithe: Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Formáid: Alt
Teanga:en_US
Foilsithe / Cruthaithe: New England Journal of Medicine 2017
Rochtain ar líne:http://hdl.handle.net/1721.1/108362
https://orcid.org/0000-0002-1446-7256

Ar líne

http://hdl.handle.net/1721.1/108362
https://orcid.org/0000-0002-1446-7256

Míreanna comhchosúla